Cargando…

Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer

We aimed to explore the value of contrast-enhanced ultrasound (CEUS) in early prediction of pathologic complete response (pCR) and recurrence-free survival (RFS) in locally advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy (NAC). LABC patients who underwent CEUS before and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Caifeng, Zhou, Liheng, Li, Hongli, Wang, Lin, Li, Fenghua, Yin, Wenjin, Wang, Yaohui, Jiang, Lixin, Lu, Jinsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378059/
https://www.ncbi.nlm.nih.gov/pubmed/37510121
http://dx.doi.org/10.3390/diagnostics13142378
_version_ 1785079671983964160
author Wan, Caifeng
Zhou, Liheng
Li, Hongli
Wang, Lin
Li, Fenghua
Yin, Wenjin
Wang, Yaohui
Jiang, Lixin
Lu, Jinsong
author_facet Wan, Caifeng
Zhou, Liheng
Li, Hongli
Wang, Lin
Li, Fenghua
Yin, Wenjin
Wang, Yaohui
Jiang, Lixin
Lu, Jinsong
author_sort Wan, Caifeng
collection PubMed
description We aimed to explore the value of contrast-enhanced ultrasound (CEUS) in early prediction of pathologic complete response (pCR) and recurrence-free survival (RFS) in locally advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy (NAC). LABC patients who underwent CEUS before and during NAC from March 2014 to October 2018 were included and assessed. Logistic regression analysis and the Cox proportional hazards model were used to identify independent variables associated with pCR and RFS. Among 122 women, 44 underwent pCR. Molecular subtype, peak intensity (PEAK) and change in diameter were independent predictors of pCR after one cycle of NAC (area under the receiver operating characteristic curve [AUC], 0.81; 95% CI: 0.73, 0.88); Molecular subtype, PEAK and change in time to peak (TTP) were independently associated with pCR after two cycles of NAC (AUC, 0.85; 95% CI: 0.77, 0.91). A higher clinical T (hazard ratio [HR] = 4.75; 95% CI: 1.75, 12.87; p = 0.002) and N stages (HR = 3.39; 95% CI: 1.25, 9.19; p = 0.02) and a longer TTP (HR = 1.06; 95% CI: 1.01, 1.11; p = 0.02) at pre-NAC CEUS were independently associated with poorer RFS. CEUS can be used as a technique to predict pCR and RFS early in LABC patients treated with NAC.
format Online
Article
Text
id pubmed-10378059
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103780592023-07-29 Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer Wan, Caifeng Zhou, Liheng Li, Hongli Wang, Lin Li, Fenghua Yin, Wenjin Wang, Yaohui Jiang, Lixin Lu, Jinsong Diagnostics (Basel) Article We aimed to explore the value of contrast-enhanced ultrasound (CEUS) in early prediction of pathologic complete response (pCR) and recurrence-free survival (RFS) in locally advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy (NAC). LABC patients who underwent CEUS before and during NAC from March 2014 to October 2018 were included and assessed. Logistic regression analysis and the Cox proportional hazards model were used to identify independent variables associated with pCR and RFS. Among 122 women, 44 underwent pCR. Molecular subtype, peak intensity (PEAK) and change in diameter were independent predictors of pCR after one cycle of NAC (area under the receiver operating characteristic curve [AUC], 0.81; 95% CI: 0.73, 0.88); Molecular subtype, PEAK and change in time to peak (TTP) were independently associated with pCR after two cycles of NAC (AUC, 0.85; 95% CI: 0.77, 0.91). A higher clinical T (hazard ratio [HR] = 4.75; 95% CI: 1.75, 12.87; p = 0.002) and N stages (HR = 3.39; 95% CI: 1.25, 9.19; p = 0.02) and a longer TTP (HR = 1.06; 95% CI: 1.01, 1.11; p = 0.02) at pre-NAC CEUS were independently associated with poorer RFS. CEUS can be used as a technique to predict pCR and RFS early in LABC patients treated with NAC. MDPI 2023-07-14 /pmc/articles/PMC10378059/ /pubmed/37510121 http://dx.doi.org/10.3390/diagnostics13142378 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wan, Caifeng
Zhou, Liheng
Li, Hongli
Wang, Lin
Li, Fenghua
Yin, Wenjin
Wang, Yaohui
Jiang, Lixin
Lu, Jinsong
Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer
title Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer
title_full Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer
title_fullStr Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer
title_full_unstemmed Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer
title_short Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer
title_sort multiparametric contrast-enhanced ultrasound in early prediction of response to neoadjuvant chemotherapy and recurrence-free survival in breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378059/
https://www.ncbi.nlm.nih.gov/pubmed/37510121
http://dx.doi.org/10.3390/diagnostics13142378
work_keys_str_mv AT wancaifeng multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer
AT zhouliheng multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer
AT lihongli multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer
AT wanglin multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer
AT lifenghua multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer
AT yinwenjin multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer
AT wangyaohui multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer
AT jianglixin multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer
AT lujinsong multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer